trial

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

NCTId NCT00338598
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 20 (actual)
Sponsored by Yale University
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2003-06
Primary completion
2015-12
Eligibility
ALL · 21 Years · 60 Years

Interventions & indications

Drugs
glycine

Sponsors

Yale UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Ismene Petrakis, M.D.Principal Investigator

Sites

1 total
West Haven, United States

Linked catalysts

1
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-mor — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE2
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
glycine
drug
lead_sponsor
Yale University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
Alcoholism
indication
investigator
Ismene Petrakis, M.D.
person